PD-L1 is considered a dynamic biomarker and might not be a valuable tool to use by itself, since its expression changes can be modulated, depending on treatment, inflammation, intratumorally/intertumoral heterogeneity, temporal heterogeneity, and expression differences between the primary and metastatic melanomas [194,413]. The gene discussed is CD274; the disease is metastatic melanoma.